- EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.
EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.
Scientific reports (2017-06-15)
Karina Thieme, Syamantak Majumder, Angela S Brijmohan, Sri N Batchu, Bridgit B Bowskill, Tamadher A Alghamdi, Suzanne L Advani, M Golam Kabir, Youan Liu, Andrew Advani
PMID28611444
ABSTRAKT
The therapeutic targeting of prostanoid subtype receptors may slow the development of chronic kidney disease (CKD) through mechanisms that are distinct from those of upstream COX inhibition. Here, employing multiple experimental models of CKD, we studied the effects of inhibition of the EP4 receptor, one of four receptor subtypes for the prostanoid prostaglandin E
MATERIAŁY